All times are listed in CEST (Central European Summer Time)
Found 2 Presentations For Request "Abs: 334P"
334P - Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients: Updated phase II results and dose selection
- Iurie Bulat (Chisinau, Moldova)
Abstract
Background
CDK4/6 inhibitors (CDK4/6i) combined with fulvestrant (F) are the established standard of care for HR+/HER2- advanced breast cancer (ABC). Two of the three approved CDK4/6i cause dose-limiting neutropenia requiring a drug holiday, and the third is limited by gastrointestinal (GI) toxicity. Lerociclib is a potent, selective CDK4/6i that is dosed continuously. Initial data presented at SABCS 2019 indicated that lerociclib + F had low rates of GI toxicity and Grade 4 neutropenia, and antitumor activity was comparable with other CDK4/6i + F combinations.
Methods
This phase I/II study assessed lerociclib with 500 mg F in patients (pts) with HR+/HER2- ABC that had progressed following endocrine therapy. Up to 2 prior chemotherapies in the advanced setting in phase I (dose escalation), and 1 prior in phase II (dose expansion) were allowed. Prior F and CDK4/6i exposure were excluded in phase II. The objectives were to evaluate DLTs, safety, tolerability, PK, preliminary efficacy, and determine the recommended dose of lerociclib when combined with F for future randomized trials.
Results
As of Jan 31, 2020, 110 pts had been enrolled across doses of 200–650 mg once daily and 100–250 mg twice daily (BID). Twenty pts received 150 mg BID for a median 6.9 (range 1.7–27.8) months, with median age of 55 years (range 33–84), ECOG of 0 (85%), and median 1 line (range 0–5) of prior anticancer therapy in the advanced setting. The most common lerociclib-related AEs at 150 mg BID were neutropenia (55%), leukopenia (40%), diarrhea (20%), and anemia (20%). Rates of Grade 3 and 4 neutropenia were 30% and 5%, respectively. There were no reports of Grade ≥ 3 nausea, vomiting, or diarrhea. Nineteen pts at 150 mg BID were evaluable for tumor response based on RECIST version 1.1. Six pts (32%) had a confirmed PR; 9 (47%) had SD; 4 (21%) had PD. The CBR (CR+PR+SD ≥ 24 weeks) was 74% (14/19). Subgroup analyses revealed that pts who received no prior chemotherapy in the advanced setting (9/19 pts) had the highest CBR of 89%.
Conclusions
Lerociclib 150 mg BID dosed continuously demonstrated a differentiated profile with low rates of GI toxicity and Grade 3/4 neutropenia. Efficacy compares favorably to approved CDK4/6i + F combinations.
Clinical trial identification
NCT02983071.
Legal entity responsible for the study
G1 Therapeutics, Inc.
Funding
G1 Therapeutics, Inc.
Disclosure
B. Krastev: Research grant/Funding (institution): G1 Therapeutics; Research grant/Funding (institution): Luitpold Pharmaceuticals; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Roche; Honoraria (self): Pfizer; Honoraria (self): MSD; Honoraria (self): Merck; Honoraria (self): Bayer; Honoraria (self): Eli Lilly; Honoraria (self): Amgen; Honoraria (self): Astellas; Honoraria (self): Mundipharma; Honoraria (self): Angelini. H-T. Arkenau: Honoraria (self), Research grant/Funding (institution): Guardant Health; Honoraria (self): Roche. R.D. Baird: Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Molecular Partners; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Shionogi; Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo; Advisory/Consultancy: Roche/Genentech; Advisory/Consultancy: Novartis; Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Research grant/Funding (institution): Sanofi; Research grant/Funding (institution): Boehringer Ingelheim; Research grant/Funding (institution): Biomarin; Research grant/Funding (institution): G1 Therapeutics; Research grant/Funding (institution): Carrick Therapeutics; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Genentech. R. Roylance: Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo; Advisory/Consultancy: Eli Lilly; Honoraria (self), Advisory/Consultancy: Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses: G1Therapeutics; Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: AstraZeneca. A.M. Wardley: Research grant/Funding (institution): G1 Therapeutics; Research grant/Funding (self): Roche; Research grant/Funding (self): Novartis; Research grant/Funding (self): Pfizer; Research grant/Funding (self): Daiichi Sankyo; Research grant/Funding (institution): Seattle Genetics; Research grant/Funding (self): Eli Lilly; Travel/Accommodation/Expenses: MSD; Research grant/Funding (self): Athenex; Research grant/Funding (self): AstraZeneca; Honoraria (self): Andrew Wardley Limited; Officer/Board of Directors: Manchester Cancer Academy; Officer/Board of Directors: Outreach Research & Innovation Group Limited; Honoraria (self): Gerson Lehman Group; Honoraria (self): Guidepoint Global; Honoraria (self): Coleman Expert Network; Honoraria (self): Helios; Honoraria (self): Health Care America. Y. Lu: Full/Part-time employment: G1 Therapeutics. A. McCullough: Full/Part-time employment: G1 Therapeutics. S. Jain: Full/Part-time employment: G1 Therapeutics. C.D. Wolfgang: Full/Part-time employment: G1 Therapeutics. R. Malik: Full/Part-time employment: G1 Therapeutics. A.P. Beelen: Full/Part-time employment: G1 Therapeutics. All other authors have declared no conflicts of interest.
1165P - Subgroup analysis by Ki-67 and primary tumour origins of the randomized, placebo-controlled phase III study of surufatinib in advanced well-differentiated extrapancreatic neuroendocrine tumours (SANET-ep)
- Zhiwei Zhou (Guangzhou, China)
Abstract
Background
Surufatinib, a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (1,2,3), fibroblast growth factor receptor 1 and colony stimulating factor 1 receptor, has demonstrated superior efficacy in extrapancreatic neuroendocrine tumors (NETs) in a phase III study (SANET-ep, ESMO 2019 Abs. LBA76). The proliferation marker Ki-67 and primary tumor origins are the major prognostic factors in NETs.
Methods
The post-hoc efficacy analysis of surufatinib versus placebo was conducted by Ki-67 subcategory (<3%, 3-10%, >10%) and primary tumor origins (foregut, midgut, hindgut, others or unknown) in patients (pts) with advanced well-differentiated (grade 1 or 2) extrapancreatic NETs. The primary endpoint (progression-free survival [PFS]) and secondary endpoint (objective response rate [ORR]) both by investigator assessment (RECIST1.1) were analyzed.
Results
Median PFS was significantly prolonged with surufatinib compared to placebo in subgroups of Ki-67 3-10% (7.6 vs 4.6 months [mo], hazard ratio [HR] 0.47,
Conclusions
Surufatinib demonstrated clinically significant benefits for pts with advanced well-differentiated extrapancreatic NETs compared to placebo. Results of this exploratory analysis were consistent with those reported for the SANET-ep primary analysis, and improved outcomes were observed across major subgroups.
Clinical trial identification
NCT02588170.
Legal entity responsible for the study
Hutchison MediPharma Limited.
Funding
Hutchison MediPharma Limited.
Disclosure
J. Li, J. He: Full/Part-time employment: Hutchison MediPharma Limited. W. Su: Shareholder/Stockholder/Stock options, Full/Part-time employment: Hutchison MediPharma Limited. All other authors have declared no conflicts of interest.